Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain

NCT05560646 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT05560646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05560646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain
Lead sponsor
Organon and Co
Phase
Phase 2
Overall status
Completed
Start date
October 25, 2022
Completion date
May 28, 2025
Enrollment
354 (actual)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

endometriosis